Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 104

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 8
Chunk 104
---
 or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to EarningsDesignated Hedging InstrumentForward currency contractsCash flow hedgeCost of products sold$99 Forward currency contractsNet investment hedgeInterest expense29 Interest rate derivative contractsCash flow hedgeInterest expense(1)

15

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:Location on Unaudited Consolidated Statements of OperationsThree Months Ended March 31,(in millions)20252024Net gain (loss) on currency hedge contractsOther, net$(42)$15 Net gain (loss) on currency transaction exposuresOther, net42 (20)Net currency exchange gain (loss)$(0)$(5)Fair Value MeasurementsFASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820), and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities: Location on Unaudited Consolidated Balance Sheets(1)As of(in millions)March 31, 2025December 31, 2024Derivative and Nonderivative Assets:   Designated Hedging Instruments  Forward currency contractsOther current assets$122 $149